Skip to main content

Advertisement

SpringerLink
Log in

Hypogonadism in the man with erectile dysfunction: What to look for and when to treat

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Hypogonadism (low serum testosterone) is commonly associated with erectile dysfunction (ED). However, many urologists may lack appreciation of the relative merits of treating hypogonadism compared with oral phosphodiesterase inhibitors for sexual dysfunction. Testosterone-replacement therapy (TRT) may be the best treatment for men with ED when the presentation includes diminished libido or other sexual symptoms or when non-sexual symptoms such as depressed mood, decreased sense of vitality, and increased fatigue also exist. The health benefits of TRT also include improvements in body composition, bone density, cognition, and sense of well-being. Thus, there may be good reasons to use TRT as first-line therapy for the man with ED. Concerns regarding prostatic and cardiovascular risks of TRT have not been supported by the literature. Nevertheless, men receiving TRT must be monitored at regular intervals with digital rectal examination and blood testing for prostate-specific antigen. Hematocrit or hemoglobin also should be obtained regularly due to the risk of erythrocytosis. Awareness of the benefits of TRT in the man with ED may improve clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Morgentaler A: Male impotence. Lancet 1999, 354:1713–1718.

    Article  PubMed  CAS  Google Scholar 

  2. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397–1414. Landmark paper reporting the first results of an effective oral agent for the treatment of ED.

    Article  PubMed  CAS  Google Scholar 

  3. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482–492. Major review of testosterone risks, detailing the lack of scientific support for traditional fears that TRT may increase the risk of prostate cancer or heart disease.

    Article  PubMed  CAS  Google Scholar 

  4. Morgentaler A: Clinical crossroads: a 66-year-old man with sexual dysfunction. JAMA 2004, 291:2994–3003.

    Article  PubMed  CAS  Google Scholar 

  5. Wang C, Swerdloff RS, Iranmanesh A, et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Endocrinol Metab 2000, 85:2839–2853.

    Article  CAS  Google Scholar 

  6. Greenstein A, Mabjeesh NJ, Sofer M, et al.: Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005, 173:530–532.

    Article  PubMed  CAS  Google Scholar 

  7. Hellstrom WJ, Gittelman M, Karlin G, et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763–771.

    PubMed  CAS  Google Scholar 

  8. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002, 168:1332–1336.

    Article  PubMed  CAS  Google Scholar 

  9. Morley JE, Kaiser FE, Perry HM, et al.: Longitudinal changes in testosterone, LH and FSH in healthy older men. Metabolism 1997, 46:410–413.

    Article  PubMed  CAS  Google Scholar 

  10. Harman SM, Metter EJ, Tobin JD, et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metabol 2001, 86:724–231.

    Article  CAS  Google Scholar 

  11. The Institute of Medicine Report: Testosterone and Aging: Clinical Research Directions. Washington DC: National Academies Press; 2004. Broad review of testosterone and hypogonadism developed at the request of the National Institute of Aging, with suggestions for which areas in particular merit research funding.

  12. Morley JE, Patrick P, Perry HM 3rd: Evaluation of assays available to measure free testosterone. Metabolism 2002, 51:554–559.

    Article  PubMed  CAS  Google Scholar 

  13. Rhoden EL, Estrada C, Levine L, Morgentaler A: The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003, 170:795–798.

    Article  PubMed  Google Scholar 

  14. Lue TF: Erectile dysfunction. N Engl J Med 2000, 342:1802–1813.

    Article  PubMed  CAS  Google Scholar 

  15. Morgantaler A, Crews D: Role of the anterior hypothalamuspreoptic area in the regulation of reproductive behavior in the lizard, Anolis carolinensis: implantation studies. Horm Behav 1978, 11:61–73.

    Article  PubMed  CAS  Google Scholar 

  16. Rajfer J, Aronson WJ, Bush PA, et al.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326:90–94.

    Article  PubMed  CAS  Google Scholar 

  17. Shabsigh R: Testosterone therapy in erectile dysfunction. Aging Male 2004, 7:312–318.

    Article  PubMed  CAS  Google Scholar 

  18. Zvara P, Sioufi R, Schipper HM, et al.: Nitric oxide-mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res 1995, 7:209–219.

    PubMed  CAS  Google Scholar 

  19. Marin R, Escrig A, Abreu P, Mas M: Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999, 61:1012–1016.

    Article  PubMed  CAS  Google Scholar 

  20. Morelli A, Filippi S, Mancina R, et al.: Androgens regulate phosphodiesterase type-5 expression and functional activity in corpora cavernosa. Endocrinology 2004, 145:2253–2263.

    Article  PubMed  CAS  Google Scholar 

  21. Amory JK, Watts NB, Easley KA, et al.: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503–510.

    Article  PubMed  CAS  Google Scholar 

  22. Swerdloff RS, Wang C, Cunningham G, et al.: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000, 85:4500–4510.

    Article  PubMed  CAS  Google Scholar 

  23. McNicholas TA, Dean JD, Mulder H, et al.: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. Br J Urol 2003, 91:69–74.

    CAS  Google Scholar 

  24. Westaby D, Ogle SJ, Paradinas FJ, et al.: Liver damage from long-term methyltestosterone. Lancet 1977, 2:262–263.

    PubMed  CAS  Google Scholar 

  25. Dobs AS, Meikle AW, Arver S, et al.: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999, 84:3469–3478.

    Article  PubMed  CAS  Google Scholar 

  26. English KM, Steeds RP, Jones TH, et al.: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 2000, 102:1906–1911.

    PubMed  CAS  Google Scholar 

  27. Webb CM, McNeill JG, Hayward CS, et al.: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999, 100:1690–1696.

    PubMed  CAS  Google Scholar 

  28. Whitsel EA, Boyko EJ, Matsumoto AM, et al.: Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001, 111:261–268.

    Article  PubMed  CAS  Google Scholar 

  29. Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173:533–536.

    Article  PubMed  CAS  Google Scholar 

  30. Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172:920–922.

    Article  PubMed  CAS  Google Scholar 

  31. Huggins CB, Stevens RB, Hodges CV: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209.

    CAS  Google Scholar 

  32. Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995, 27:25–31.

    Article  PubMed  CAS  Google Scholar 

  33. Heikkila R, Aho K, Heliovaara M, et al.: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999, 86:312–315.

    Article  PubMed  CAS  Google Scholar 

  34. Gann PH, Hennekens CH, Ma J, et al.: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88:1118–1126.

    Article  PubMed  CAS  Google Scholar 

  35. Hsing AW: Hormones and prostate cancer: What’s next? Epidemiologic Rev 2001, 23:42–58.

    CAS  Google Scholar 

  36. Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348–2351. High-risk group fails to demonstrate increased prostate cancer risk with testosterone treatment.

    Article  PubMed  CAS  Google Scholar 

  37. Morgentaler A, Bruning CO, DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 1996, 276:1904–1906.

    Article  PubMed  CAS  Google Scholar 

  38. Rhoden EL, Morgentaler A: Results of prostate biopsy in men with low serum testosterone. J Urol 2003, 169:S119.

    Google Scholar 

  39. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum-free testosterone a marker for high-grade prostate cancer? J Urol 2000, 163:824–827.

    Article  PubMed  CAS  Google Scholar 

  40. Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299–311.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Men’s Health Boston, One Brookline Place #624, 02445, Brookline, MA, USA

    Abraham Morgentaler MD

Authors
  1. Stephen Lazarou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abraham Morgentaler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lazarou, S., Morgentaler, A. Hypogonadism in the man with erectile dysfunction: What to look for and when to treat. Curr Urol Rep 6, 476–481 (2005). https://doi.org/10.1007/s11934-005-0044-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0044-z

Keywords

Search

Navigation